Acumen Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $104.9M | $93.8M | $42.3M | $32.4M | $12.3M |
| Operating expenses | $123.8M | $114.0M | $61.1M | $45.2M | $19.6M |
| Operating income | -$123.8M | -$114.0M | -$61.1M | -$45.2M | -$19.6M |
| Interest expense | $4.2M | $4.1M | $581,000 | $0 | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M | -$100.6M |
| Balance Sheet | |||||
| Cash and equivalents | $54.0M | $35.6M | $66.9M | $130.1M | $122.2M |
| Current assets | $122.3M | $178.3M | $246.6M | $180.3M | $198.7M |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M |
| Current liabilities | $30.0M | $27.6M | $13.0M | $7.8M | $5.1M |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M |
| Total debt | $31.2M | $29.4M | — | — | — |
| Stockholders' equity | $70.4M | $181.8M | $267.0M | $188.8M | $225.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$115.5M | -$86.2M | -$43.1M | -$35.2M | -$18.0M |
| Depreciation and amortization | $58,000 | $63,000 | $61,000 | $32,000 | $4,000 |
| Stock-based compensation | $9.9M | $9.6M | $6.1M | $3.1M | $922,000 |
| Capital expenditure | $88,000 | $16,000 | $21,000 | $161,000 | $40,000 |
| Free cash flow | -$115.6M | -$86.2M | -$43.1M | -$35.3M | -$18.0M |
Shares outstanding 72.2M · Free float 54.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.